Advertisement

Construction of Targeted and Armed Oncolytic Adenoviruses

  • Konstantin Doronin
  • Dmitry M. Shayakhmetov
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 797)

Abstract

Oncolytic (replication-competent) adenoviruses (Ads) represent the most advanced platform for cancer gene therapy. These viral vectors ablate tumors by killing tumor cells in the process of virus replication. As progeny virions are released, they infect remaining cancer cells, generating a bystander effect. Ads engineered for increased cancer specificity produce less damage to normal tissues. First-generation oncolytic Ads have demonstrated acceptable levels of safety while the efficacy was observed only in combination with chemotherapy and/or radiation. Second-generation oncolytic Ads are armed with therapeutic transgenes to increase release, spread, and bystander effect for enhancing the efficacy. Third-generation oncolytic Ads are armed vectors with capsid modifications for transductional detargeting from normal tissues and targeting to cancer cells. Chemical modification of the capsid additionally improves therapeutic window. Here, we describe methods for generation and characterization of advanced-generation oncolytic Ads.

Key words

Adenovirus Oncolytic virotherapy Genetic vectors Animal models Experimental neoplasms 

Notes

Acknowledgment

This work was supported by R01CA141439 to D.M. Shayakhmetov.

References

  1. 1.
    Graham, F. L., Smiley, J., Russell, W. C., and Nairn, R. (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 36, 59–74.Google Scholar
  2. 2.
    Huebner, R. J., Rowe, W. P., Schatten, W. E., Smith, R. R., and Thomas, L. B. (1956) Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer. 9, 1211–1218.Google Scholar
  3. 3.
    Liu, T. C., Galanis, E., and Kirn, D. (2007) Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol. 4, 101–117.Google Scholar
  4. 4.
    Yamamoto, M. and Curiel, D. T. (2010) Current issues and future directions of oncolytic adenoviruses. Mol Ther. 18, 243–250.Google Scholar
  5. 5.
    Doronin, K., Toth, K., Kuppuswamy, M., Ward, P., Tollefson, A. E., and Wold, W. S. (2000) Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol. 74, 6147–6155.Google Scholar
  6. 6.
    Doronin, K., Kuppuswamy, M., Toth, K., Tollefson, A. E., Krajcsi, P., Krougliak, V., et al. (2001) Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J Virol. 75, 3314–3324.Google Scholar
  7. 7.
    Shashkova, E. V., Kuppuswamy, M. N., Wold, W. S., and Doronin, K. (2008) Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL. Cancer Gene Ther. 15, 61–72.Google Scholar
  8. 8.
    Shayakhmetov, D. M., Papayannopoulou, T., Stamatoyannopoulos, G., and Lieber, A. (2000) Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J Virol. 74, 2567–2583.Google Scholar
  9. 9.
    Doronin, K., Shashkova, E. V., May, S. M., Hofherr, S. E., and Barry, M. A. (2009) Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum Gene Ther. 20, 975–988.Google Scholar
  10. 10.
    Shashkova, E. V., Spencer, J. F., Wold, W. S., and Doronin, K. (2007) Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus. Mol Ther. 15, 598–607.Google Scholar
  11. 11.
    Sauthoff, H., Pipiya, T., Heitner, S., Chen, S., Bleck, B., Reibman, J., et al. (2004) Impact of E1a modifications on tumor-selective adenoviral replication and toxicity. Mol Ther. 10, 749–757.Google Scholar
  12. 12.
    Krougliak, V. and Graham, F. L. (1995) Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants. Hum Gene Ther. 6, 1575–1586.Google Scholar
  13. 13.
    Chen, C. and Okayama, H. (1987) High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol. 7, 2745–2752.Google Scholar
  14. 14.
    Kuppuswamy, M., Spencer, J. F., Doronin, K., Tollefson, A. E., Wold, W. S., and Toth, K. (2005) Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression. Gene Ther. 12, 1608–1617.Google Scholar
  15. 15.
    Bett, A. J., Haddara, W., Prevec, L., and Graham, F. L. (1994) An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA. 91, 8802–8806.Google Scholar
  16. 16.
    Gaggar, A., Shayakhmetov, D. M., and Lieber, A. (2003) CD46 is a cellular receptor for group B adenoviruses. Nat Med. 9, 1408–1412.Google Scholar
  17. 17.
    Sova, P., Ren, X. W., Ni, S., Bernt, K. M., Mi, J., Kiviat, N., et al. (2004) A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol Ther. 9, 496–509.Google Scholar
  18. 18.
    Mizuguchi, H. and Kay, M. A. (1998) Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther. 9, 2577–2583.Google Scholar
  19. 19.
    Kalyuzhniy, O., Di Paolo, N. C., Silvestry, M., Hofherr, S. E., Barry, M. A., Stewart, P. L., et al. (2008) Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci USA. 105, 5483–5488.Google Scholar
  20. 20.
    Alba, R., Bradshaw, A. C., Parker, A. L., Bhella, D., Waddington, S. N., Nicklin, S. A., et al. (2009) Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood. 114, 965–971.Google Scholar
  21. 21.
    Shashkova, E. V., May, S. M., Doronin, K., and Barry, M. A. (2009) Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus. Mol Ther. 17, 2121–2130.Google Scholar
  22. 22.
    Campos, S. K. and Barry, M. A. (2004) Rapid construction of capsid-modified adenoviral vectors through bacteriophage lambda Red recombination. Hum Gene Ther. 15, 1125–1130.Google Scholar
  23. 23.
    Graham, F. L. (1987) Growth of 293 cells in suspension culture. J Gen Virol. 68 (Pt 3), 937–940.Google Scholar
  24. 24.
    O’Riordan, C. R., Lachapelle, A., Delgado, C., Parkes, V., Wadsworth, S. C., Smith, A. E., et al. (1999) PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther. 10, 1349–1358.Google Scholar
  25. 25.
    Shashkova, E. V., Doronin, K., Senac, J. S., and Barry, M. A. (2008) Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus. Cancer Res. 68, 5896–5904.Google Scholar
  26. 26.
    Duncan, S. J., Gordon, F. C., Gregory, D. W., McPhie, J. L., Postlethwaite, R., White, R., et al. (1978) Infection of mouse liver by human adenovirus type 5. J Gen Virol. 40, 45–61.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Division of Medical GeneticsUniversity of WashingtonSeattleUSA
  2. 2.University of WashingtonSeattleUSA

Personalised recommendations